NASDAQ:KLDO Kaleido Biosciences (KLDO) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free KLDO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume652 shsAverage Volume4,185 shsMarket Capitalization$4,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSocial Media Get Kaleido Biosciences alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Kaleido Biosciences Stock (NASDAQ:KLDO)Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 KLDO Stock News HeadlinesApril 5, 2024 | fool.comKaleido Biosciences (OTC: KLDO)April 4, 2024 | finance.yahoo.comKaleido and Emma Join Forces to Help Families Secure Their Financial Future: An Innovative PartnershipApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 2, 2024 | finance.yahoo.comChange in management Kaleido IDEO+ individual RESP portfoliosDecember 20, 2023 | finance.yahoo.comMobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido IntelligenceDecember 20, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: Mobile Roaming Revenues to Reach $45 Billion In 2024: Kaleido IntelligenceDecember 14, 2023 | finance.yahoo.comKaleido Intelligence to Launch Huge Enterprise Connectivity Survey in 2024November 22, 2023 | finanznachrichten.deViCentra: Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetesApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinNovember 14, 2023 | finance.yahoo.comEseye, G+D, Thales and Vodafone Recognised as Champion Connectivity Vendors by Kaleido IntelligenceNovember 7, 2023 | bizjournals.comLocal tech startup brings augmented reality to art marketNovember 5, 2023 | morningstar.comKaleido Biosciences Inc KLDOOctober 24, 2023 | finance.yahoo.comNokia and NTT DATA Recognised as Champion Private Network Vendors by Kaleido IntelligenceOctober 16, 2023 | tmcnet.comSyniverse Named Leader in Mobile Roaming by Kaleido Intelligence for Third Straight YearOctober 12, 2023 | finanznachrichten.deBroadForward earns top rating from Kaleido for BroadForward Signaling Security and Firewall productsOctober 10, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: BICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido IntelligenceOctober 10, 2023 | finance.yahoo.comBICS, Cellusys, Comfone, iBASIS, Mobileum & Syniverse Leads Champion Roaming Vendors: Kaleido IntelligenceSeptember 13, 2023 | msn.comKaleido Family Arts Festival crowdfunding after grant cuts leave it $50K shortAugust 26, 2023 | seekingalpha.comIDXG Interpace Biosciences, Inc.August 21, 2023 | tmcnet.comeSIM/iSIM Shipments to Exceed 1.4 Billion in 2028, Propelled by Ecosystem Simplification: Kaleido IntelligenceAugust 6, 2023 | finance.yahoo.comKLDO - Kaleido Biosciences, Inc.June 20, 2023 | technews.tmcnet.comIoT Wholesale Roaming Revenue to Exceed $8 Billion in 2028: Kaleido IntelligenceJune 3, 2023 | benzinga.comKaleido Creative Studio Launches OnNiche™: A Niche-Based Marketing System for Financial AdvisorsApril 26, 2023 | finanznachrichten.deKALEIDO INTELLIGENCE LIMITED: Kaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028April 26, 2023 | tmcnet.comKaleido Intelligence Expects 848 Million Telematics and Infotainment Cellular Subscriptions to be Active by 2028March 28, 2023 | marketwatch.comConsumer & IoT Mobile Roaming Data Traffic Expected to Triple 2019 Volume, Approaching 3,000 Petabytes in 2023: Kaleido IntelligenceFebruary 22, 2023 | yahoo.comDirect-To-Satellite Communications to Generate $9 Billion in Airtime Revenues for Operators in 2030: Kaleido IntelligenceSee More Headlines Receive KLDO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KLDO CUSIPN/A CIK1751299 Webwww.kaleido.com Phone(617) 674-9000FaxN/AEmployees76Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares42,623,000Free Float38,787,000Market Cap$4,262.30 OptionableNot Optionable Beta-0.06 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Kimberly HocknellSenior Vice President of Technical OperationsDr. Mark A. Wingertzahn Ph.D. (Age 52)Senior VP of R&D and Head of Development Key CompetitorsHTG Molecular DiagnosticsNASDAQ:HTGMQGenocea BiosciencesNASDAQ:GNCAViveve MedicalNASDAQ:VIVEOncoSec MedicalNASDAQ:ONCSQAllied Healthcare ProductsNASDAQ:AHPIView All Competitors KLDO Stock Analysis - Frequently Asked Questions How have KLDO shares performed in 2024? Kaleido Biosciences' stock was trading at $0.0001 on January 1st, 2024. Since then, KLDO stock has increased by 0.0% and is now trading at $0.0001. View the best growth stocks for 2024 here. How were Kaleido Biosciences' earnings last quarter? Kaleido Biosciences, Inc. (NASDAQ:KLDO) announced its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.25 million. What other stocks do shareholders of Kaleido Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK). When did Kaleido Biosciences IPO? Kaleido Biosciences (KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of Kaleido Biosciences? Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KLDO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kaleido Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
